Reported Standalone quarterly numbers for Sun Pharma Advanced Research Company are:
Net Sales at Rs 31.54 crore in September 2022 up 13.17% from Rs. 27.87 crore in September 2021.
Story continues below Advertisement
Quarterly Net Loss at Rs. 68.40 crore in September 2022 down 24.05% from Rs. 55.14 crore in September 2021.
EBITDA stands negative at Rs. 62.54 crore in September 2022 down 27.14% from Rs. 49.19 crore in September 2021.
Sun Pharma Adv shares closed at 254.65 on November 07, 2022 (NSE) and has given 9.08% returns over the last 6 months and -5.70% over the last 12 months.
Story continues below Advertisement
| Sun Pharma Advanced Research Company | | Standalone Quarterly Results | in Rs. Cr. |
|
| Sep'22 | Jun'22 | Sep'21 | | Net Sales/Income from operations | 31.54 | 28.46 | 27.87 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 31.54 | 28.46 | 27.87 | | EXPENDITURE | | Consumption of Raw Materials | 5.58 | 5.70 | 5.35 | | Purchase of Traded Goods | -- | -- | -- | | Increase/Decrease in Stocks | -- | -- | -- | | Power & Fuel | -- | -- | -- | | Employees Cost | 25.32 | 25.05 | 23.94 | | Depreciation | 3.00 | 2.70 | 2.54 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 63.24 | 75.91 | 53.75 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -65.60 | -80.90 | -57.71 | | Other Income | 0.06 | 0.18 | 5.98 | | P/L Before Int., Excpt. Items & Tax | -65.54 | -80.72 | -51.73 | | Interest | 2.86 | 1.63 | 3.41 | | P/L Before Exceptional Items & Tax | -68.40 | -82.35 | -55.14 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | -68.40 | -82.35 | -55.14 | | Tax | -- | -- | -- | | P/L After Tax from Ordinary Activities | -68.40 | -82.35 | -55.14 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -68.40 | -82.35 | -55.14 | | Equity Share Capital | 27.19 | 27.19 | 26.35 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -2.52 | -3.03 | -2.09 | | Diluted EPS | -2.52 | -3.03 | -2.09 | | EPS After Extra Ordinary | | Basic EPS | -2.52 | -3.03 | -2.09 | | Diluted EPS | -2.52 | -3.03 | -2.09 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
